21st October, 2015

The Chief Manager
Surveillance,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir,

Sub : **Confirmation/Information on published news**

This is with reference to your Letter No. NSE/CM/Surveillance/R-126 dated 21.10.2015 regarding the news item which appeared on "ET NOW" dated October 21, 2015 captioned "Torrent Pharma gets approval for generic version of NEXIUM"

Torrent Pharmaceuticals Limited has received the approval from United States Food and Drugs Administration for marketing of generic version of NEXIUM. The generic product for NEXIUM is Esomeprazole Magnesium.

The generic version of NEXIUM is currently being marked by the following Companies in the US market.

1. Teva Pharmaceuticals, Inc.
2. Dr. Reddy's Labs Ltd.
3. Mylan Pharmaceuticals Inc.
4. Hetero Labs. Ltd..

For marketing pharmaceutical products in any country, the Company requires the approval of the Drug Regulatory Authority of the respective country. Torrent Pharma is marketing its products in India and in various countries across the globe including US, Brazil, Germany, Mexico, UK, Russia, among others. It seeks and receives the approval of various products in various countries as an integral part of its business operations. Accordingly, the approval for marketing of Esomeprazole Magnesium for the US market was applied for and has been received on 19th October, 2015.

As a responsible listed organization, we do inform the exchanges of all information which is required to be disclosed, on timely basis, in terms of the Listing Agreement and will keep the exchange informed in future as well.

Thanks & Regards,
For **Torrent Pharmaceuticals Limited**

Mahesh Agrawal
VP (Legal) & Company Secretary